FDA Grants Breakthrough Device Designation to Biosignature Test in DCIS
The DCISionRT test has shown to be a significant factor in a clinician’s recommendation on whether a patient with DCIS should receive radiotherapy.
SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care
Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.
Seattle-based Clinicians on Effective Treatment Combos in EGFR-Mutated NSCLC
A panel of experts met to discuss the best treatment options for patients with EGFR or TP53-mutated non–small cell lung cancer.
Using Multidisciplinary Lifestyle Medicine to Enhance Cancer Survivor QOL
Authors of an article published in ONCOLOGY® detail how a novel multidisciplinary lifestyle medicine clinic can meet the needs of cancer survivors.
NSCLC Experts Ponder Best First-Line Treatment Options
The discussion on NSCLC narrowed in on findings from recent clinical trials, particularly involving a combination regimen of amivantamab plus lazertinib vs osimertinib and chemotherapy.
University of Chicago Thought Process on First-line Treatment in EGFR NSCLC
Referring to the NCCN guidelines for the treatment of EGFR-mutated NSCLC will help clinicians determine which treatments are best recommended.
